Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models

Chemoresistance, particularly to gemcitabine, is a major challenge in pancreatic cancer. The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptors 2 and 3 (HER2, HER3) are expressed in many tumors, and they are relevant therapeutic targets due to their synergistic inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabia, Emilia, Garambois, Véronique, Hubert, Julie, Bruciamacchie, Marine, Pirot, Nelly, Delpech, Hélène, Broyon, Morgane, Theillet, Charles, Colombo, Pierre-Emmanuel, Vie, Nadia, Tosi, Diego, Gongora, Celine, Khellaf, Lakhdar, Jarlier, Marta, Radosevic-Robin, Nina, Chardès, Thierry, Pèlegrin, André, Larbouret, Christel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078530/
https://www.ncbi.nlm.nih.gov/pubmed/33876707
http://dx.doi.org/10.1080/19420862.2021.1914883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078530/
https://www.ncbi.nlm.nih.gov/pubmed/33876707
http://dx.doi.org/10.1080/19420862.2021.1914883

Ejemplares similares